No Data
Baidu Bayesian-B (02315): Earnings performance exceeded expectations, driving a new round of value reassessment.
As the performance reaches a profitability turning point, the subsequent valuation increase of Bai Ao Sai Tu has become a highly probable event, warranting more attention from the market.
Understand at a glance | Highlights of Baiao Saitu's 2024 annual performance.
Source: Bai'ao Saitou.
Bai'ao Saitou-B (02315.HK) has impressive performance in 2024: revenue surged by 36.8%, with accelerated global pharmaceutical collaboration.
On March 26, Glorious Holdings announced its annual performance for Bai Aosai Tu-B (02315.HK). In the fiscal year 2024, the group achieved revenue of 0.9805 billion yuan, continuing rapid growth with an increase of approximately 36.8% compared to the same period last year; net income reached 33.5 million yuan, achieving a turnaround from loss to profit year-on-year; net inflow of cash from operating activities was 0.2112 billion yuan. The fiscal year 2024 is a milestone year for the company, achieving a turnaround to profit for the full year based on positive operating cash flow in the first half of the year. The successful completion of the profit turnaround goal marks the group's Global Strategy adjustment and.
BIOCYTOGEN-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31, 2024
BioAsia Tech-B (02315.HK) plans to hold a Board of Directors meeting on March 26 to approve the annual performance.
Glory Capital announced on March 14 that the Board of Directors meeting for Baio Saitu-B (02315.HK) will be held on March 26, 2025 (Wednesday) to (including) (i) consider and approve the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and its publication, and (ii) consider the payment of the final dividend (if any).
BIOCYTOGEN-B: DATE OF BOARD MEETING
meowmeow66 : I dont think moomoo can order this IPO. you can ask customer service to double check.